Copyright tradingview
Hims and Hers Health HIMS beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings. The company and rivals have launched programs that offer "personalized" versions of semaglutide, the active ingredient in weight-loss drug Wegovy, at doses not accessible through the branded manufacturers, following the government's ban on the mass production of copies of those drugs. Hims and Hers' subscriber base increased to 2.47 million, up 21% from the prior year, while monthly online revenue per average subscriber climbed 19% to $80. Shares of the company were up about 3% in after-market trading on Monday. Its quarterly revenue came in at $600 million, exceeding analysts' estimates of $580.2 million The company reported an adjusted profit of 6 cents per share for the quarter ended September 30, lower than the average analyst estimate of 10 cents per share, according to LSEG data.
